US 12,274,707 B2
Methods of treating chronic kidney disease with dapagliflozin
Anna Maria Langkilde, Södertälje (SE)
Assigned to AstraZeneca AB, Södertälje (SE)
Filed by ASTRAZENECA AB, Södertälje (SE)
Filed on Apr. 1, 2021, as Appl. No. 17/219,992.
Claims priority of provisional application 63/161,629, filed on Mar. 16, 2021.
Claims priority of provisional application 63/152,445, filed on Feb. 23, 2021.
Claims priority of provisional application 63/119,711, filed on Dec. 1, 2020.
Claims priority of provisional application 63/093,961, filed on Oct. 20, 2020.
Claims priority of provisional application 63/082,524, filed on Sep. 24, 2020.
Claims priority of provisional application 63/070,869, filed on Aug. 27, 2020.
Claims priority of provisional application 63/057,139, filed on Jul. 27, 2020.
Prior Publication US 2022/0023252 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7004 (2006.01); A61K 9/00 (2006.01); A61K 31/351 (2006.01); A61K 31/401 (2006.01); A61K 31/41 (2006.01); A61K 31/4178 (2006.01); A61K 45/06 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/7004 (2013.01) [A61K 9/0053 (2013.01); A61K 31/351 (2013.01); A61K 31/401 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 45/06 (2013.01); A61P 13/12 (2018.01)] 24 Claims
 
1. A method of treating a patient with chronic kidney disease at risk of progression, comprising administering once daily to the patient a pharmaceutical composition comprising a therapeutically effective amount of dapagliflozin,
wherein the patient does not have type II diabetes,
wherein dapagliflozin is administered for at least four months, and
wherein the method reduces a risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and hospitalization for heart failure in the patient relative to a dosing regimen in which the patient receives no dapagliflozin.